FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4299458342> ?p ?o ?g. }

• W4299458342 endingPage "198" @default.
• W4299458342 startingPage "191" @default.
• W4299458342 abstract "Introduction: Trastuzumab emtansine (T-DM1) is one of the effective treatment options in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients. In this study, we aimed to find the effect of T-DM1 on survival, its tolerability and prognostic factors of T-DM1 treatment. Material and methods: The study was designed as a single-center, retrospective study that included patients treated in the oncology department of a university hospital in Turkey. HER2-positive patients with metastatic breast cancer who had a progression response to trastuzumab and taxane treatment and received T-DM1 treatment for at least 2 months between 2016-2022 were included in the study. Adverse events were defined according to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE). Kaplan-Meier methodology and Cox proportional hazard modelling were used for survival analyses. Results: The median progression-free survival (mPFS) for T-DM1 was 10.4 months and the median overall survival (mOS) was 22 months. In the created univariate cox regression model, liver metastasis, ECOG performance status, and pre-treatment serum CA 15-3 were found to be factors associated with PFS. Liver metastasis (HR=2.54, p=0.019), ECOG performance status (HR=4.66, p=0.002), and serum CA 15-3 (HR= 2.55, p=0.041) maintained their statistical significance for PFS in the established multivariate analysis. In the regression analysis for OS, only ECOG performance status (HR= 2.61, p=0.023) was found to be prognostic. While toxicity occurred in 46 (82.1%) of the patients, grade 3-4 toxicity developed in 10 (17.9%) patients. The most common side effects were anemia, thrombocytopenia, fatigue and nausea. Conclusions: T-DM1 is a safe and tolerable agent that prolongs survival. Liver metastasis, ECOG performance status, and pre-treatment serum CA 15-3 levels are independent prognostic factors for patients using T-DM1." @default.
• W4299458342 created "2022-10-02" @default.
• W4299458342 creator A5043498541 @default.
• W4299458342 creator A5053054460 @default.
• W4299458342 creator A5064417858 @default.
• W4299458342 creator A5078547021 @default.
• W4299458342 creator A5080803322 @default.
• W4299458342 date "2022-08-23" @default.
• W4299458342 modified "2023-09-26" @default.
• W4299458342 title "Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study" @default.
• W4299458342 cites W1863700672 @default.
• W4299458342 cites W1968590850 @default.
• W4299458342 cites W1968813883 @default.
• W4299458342 cites W1984007340 @default.
• W4299458342 cites W1996755397 @default.
• W4299458342 cites W2082818260 @default.
• W4299458342 cites W2083442629 @default.
• W4299458342 cites W2098460073 @default.
• W4299458342 cites W2159967578 @default.
• W4299458342 cites W2267844613 @default.
• W4299458342 cites W2297381223 @default.
• W4299458342 cites W2393325472 @default.
• W4299458342 cites W2595081519 @default.
• W4299458342 cites W2614773797 @default.
• W4299458342 cites W2619710211 @default.
• W4299458342 cites W2774481898 @default.
• W4299458342 cites W2887448630 @default.
• W4299458342 cites W2896524087 @default.
• W4299458342 cites W2901397663 @default.
• W4299458342 cites W2902218997 @default.
• W4299458342 cites W2912923142 @default.
• W4299458342 cites W2914242007 @default.
• W4299458342 cites W3027348319 @default.
• W4299458342 cites W3128646645 @default.
• W4299458342 cites W3135149529 @default.
• W4299458342 cites W3160931700 @default.
• W4299458342 cites W3161506837 @default.
• W4299458342 cites W4206299960 @default.
• W4299458342 cites W4206548876 @default.
• W4299458342 cites W4211123279 @default.
• W4299458342 cites W4220930291 @default.
• W4299458342 cites W4234081105 @default.
• W4299458342 doi "https://doi.org/10.53986/ibjm.2022.0033" @default.
• W4299458342 hasPublicationYear "2022" @default.
• W4299458342 type Work @default.
• W4299458342 citedByCount "0" @default.
• W4299458342 crossrefType "journal-article" @default.
• W4299458342 hasAuthorship W4299458342A5043498541 @default.
• W4299458342 hasAuthorship W4299458342A5053054460 @default.
• W4299458342 hasAuthorship W4299458342A5064417858 @default.
• W4299458342 hasAuthorship W4299458342A5078547021 @default.
• W4299458342 hasAuthorship W4299458342A5080803322 @default.
• W4299458342 hasBestOaLocation W42994583421 @default.
• W4299458342 hasConcept C121608353 @default.
• W4299458342 hasConcept C126322002 @default.
• W4299458342 hasConcept C143998085 @default.
• W4299458342 hasConcept C197934379 @default.
• W4299458342 hasConcept C207103383 @default.
• W4299458342 hasConcept C2775930923 @default.
• W4299458342 hasConcept C2776694085 @default.
• W4299458342 hasConcept C2776907518 @default.
• W4299458342 hasConcept C2777793932 @default.
• W4299458342 hasConcept C2778087150 @default.
• W4299458342 hasConcept C2778375690 @default.
• W4299458342 hasConcept C2779786085 @default.
• W4299458342 hasConcept C2780073493 @default.
• W4299458342 hasConcept C2780739268 @default.
• W4299458342 hasConcept C44249647 @default.
• W4299458342 hasConcept C50382708 @default.
• W4299458342 hasConcept C530470458 @default.
• W4299458342 hasConcept C71924100 @default.
• W4299458342 hasConceptScore W4299458342C121608353 @default.
• W4299458342 hasConceptScore W4299458342C126322002 @default.
• W4299458342 hasConceptScore W4299458342C143998085 @default.
• W4299458342 hasConceptScore W4299458342C197934379 @default.
• W4299458342 hasConceptScore W4299458342C207103383 @default.
• W4299458342 hasConceptScore W4299458342C2775930923 @default.
• W4299458342 hasConceptScore W4299458342C2776694085 @default.
• W4299458342 hasConceptScore W4299458342C2776907518 @default.
• W4299458342 hasConceptScore W4299458342C2777793932 @default.
• W4299458342 hasConceptScore W4299458342C2778087150 @default.
• W4299458342 hasConceptScore W4299458342C2778375690 @default.
• W4299458342 hasConceptScore W4299458342C2779786085 @default.
• W4299458342 hasConceptScore W4299458342C2780073493 @default.
• W4299458342 hasConceptScore W4299458342C2780739268 @default.
• W4299458342 hasConceptScore W4299458342C44249647 @default.
• W4299458342 hasConceptScore W4299458342C50382708 @default.
• W4299458342 hasConceptScore W4299458342C530470458 @default.
• W4299458342 hasConceptScore W4299458342C71924100 @default.
• W4299458342 hasIssue "4" @default.
• W4299458342 hasLocation W42994583421 @default.
• W4299458342 hasOpenAccess W4299458342 @default.
• W4299458342 hasPrimaryLocation W42994583421 @default.
• W4299458342 hasRelatedWork W2622612196 @default.
• W4299458342 hasRelatedWork W2905960639 @default.
• W4299458342 hasRelatedWork W2939485277 @default.
• W4299458342 hasRelatedWork W2944154894 @default.
• W4299458342 hasRelatedWork W3088751691 @default.

• next